Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/1031
Title: Gemcitabine and betulinic acid co-encapsulated PLGA−PEG polymer nanoparticles for improved efficacy of cancer chemotherapy
Authors: Panda, Amulya Kumar
Saneja, Ankit
Kumar, Robin
Mintoo, Mubashir J.
Dubeya, Ravindra Dhar
Sangwan, Payare Lal
Mondhe, Dilip M.
Gupta, Prem N
Keywords: Nanoparticles Gemcitabine Betulinic acid Co-delivery Solid tumor
Issue Date: May-2019
Publisher: Elsevier B.V.
Abstract: The present study demonstrated the development of gemcitabine and betulinic acid co-encapsulated PLGA-PEG polymer nanoparticles for enhancing the chemotherapeutic response. This combinatorial PLGA-PEG nanoparticle was formulated using double emulsion and had size <200 nm. The developed nanoparticles were characterized using dynamic light scattering and transmission electron microscopy for their size and shape, respectively. The in vitro release of the drugs from combinatorial nanoparticles was predominantly followed by Fickian diffusion phenomenon. Study on hemocompatibilty approved the administration of this combinatorial nanoparticle for animal study. In vitro cytotoxicity study on Panc1 cells using MTT assay, reactive oxygen species production and cellular apoptotic assay demonstrated that combinatorial nanoparticle was more cytotoxic compared to native drugs solution. Furthermore, the combinatorial nanoparticle suppressed tumor growth more efficiently in Ehrlich (solid) tumor model than the native gemcitabine and betulinic acid at the same concentrations. These findings indicated that PLGA-PEG nanoparticle might be used to co-deliver multiple chemotherapeutic drugs with different properties for enhancing antitumor efficacy.
URI: http://hdl.handle.net/123456789/1031
Appears in Collections:Product Development Cell Unit- II, Publications

Files in This Item:
File Description SizeFormat 
1-s2.0-S092849311832589X-main.pdfResearch Article1.86 MBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.